aaiPharma Inc. Wilmington, North Carolina
aaiPharma Inc. is a science-based, specialty pharmaceutical company with more than 22 years of drug development experience. Focusing on targeted therapeutic areas, the Company markets a growing portfolio of established branded products and applies innovative technologies to increase the commercial potential of these products. At the same time, aaiPharma's research and development organization is developing an impressive pipeline of products to position the Company for near-term and long-term growth in its targeted therapeutic areas. In addition to developing and marketing its own line of proprietary pharmaceutical products, aaiPharma continues to be a world leader in providing contract pharmaceutical development services through its AAI International division. NOTE: Merger with CIMA Labs announced 8/05/2003, terminated 11/03/2003.
Abbott Laboratories, Inc. Abbott Park, Ilinois
For more than a century, Abbott Laboratories has been working to advance health care for people around the world. Founded by a young Chicago physician, Dr. Wallace Calvin Abbott, in 1888, Abbott Laboratories has evolved into a diversified health care company that discovers, develops, manufactures and markets innovative products and services that span the continuum of care – from prevention and diagnosis to treatment and cure. Headquartered in north suburban Chicago, Abbott helps people around the world in the more than 130 countries.
Building leadership and combining strengths in the areas of pharmaceuticals, nutritionals, hospital products and diagnostics has enabled Abbott to provide total, integrated solutions across the health care spectrum for some of the world’s most prevalent medical conditions, including AIDS, cancer and diabetes. We focus on advancing medical science and the practice of health care with expertise in the therapeutic areas of diabetes, pain management, respiratory infections, HIV/AIDS, men and women’s health, pediatrics and animal health.
Abgenix, Inc. Fremont, California
We are a biopharmaceutical company that develops and intends to commercialize antibody therapeutic products for the treatment of a variety of disease conditions, including cancer, inflammatory and autoimmune disorders, transplant-related diseases, cardiovascular disease and infectious diseases. We have proprietary technologies that facilitate rapid generation of highly specific, antibody therapeutic product candidates that contain fully human protein sequences and that bind to disease targets appropriate for antibody therapy. We refer to these candidates as fully human antibody therapeutic candidates. We developed our XenoMouse® technology, a technology using genetically modified mice to generate fully human antibodies. We also own a technology that enables the rapid identification of antibodies with desired function and characteristics, referred to as SLAM™ technology. In our XenoMax™ technology, we use SLAM technology to select and isolate antibodies with particular function and characteristics from antibody-producing cells generated by XenoMouse animals. We believe XenoMax technology enhances our capabilities in product development and flexibility in manufacturing. We intend to use our technologies to build a large and diversified product portfolio that we expect to develop and commercialize through licensing arrangements with pharmaceutical companies and others, through joint development and through internal product development programs. We have entered into a variety of contractual arrangements with multiple pharmaceutical, biotechnology and genomics companies involving our XenoMouse technology. Two of our customers, Pfizer and Amgen, have initiated clinical trials with fully human antibodies generated from XenoMouse animals. In addition, as of March 31, 2002, we had four proprietary antibody product candidates in clinical trials, one of which we had agreed to co-develop and commercialize with Immunex Corporation and one of which we had agreed to co-develop and commercialize with SangStat Medical Corporation.
ActivBiotics, Inc. 128 Spring Street Lexington, Massachusetts 02421
ActivBiotics is a clinical stage company committed to significantly improving the treatment of acute infections and chronic diseases caused or exacerbated by microbial pathogens. The Company's lead compound, rifalazil, is being investigated in a Phase II trial for sexually transmitted diseases and is preparing to enter Phase II trials in other indications. In addition, the Company has a highly productive program to develop proprietary new chemical entities. The program is producing both narrow and broad spectrum compounds with unprecedented potency and concomitantly improved resistance profile. Email: info@activbiotics.com
Adolor Corporation Exton, Pennsylvania
Adolor Corporation is a late-stage biopharmaceutical company committed to the development and commercialization of novel products to relieve pain and reduce the side effects of currently marketed narcotics. Adolor’s lead product candidate, alvimopan™, is a first-in-class compound that is in Phase 3 clinical trials for two indications: post-operative ileus and opioid bowel dysfunction, both of which represent large unmet medical needs. The company is also developing a series of next-generation peripherally acting kappa opioid compounds for the treatment of pain associated with acute and chronic inflammatory diseases. These compounds have the potential to revolutionize existing pain management markets because of their ability to relieve pain as effectively as morphine and other opioid narcotics, without the severe adverse side effects and addiction potential associated with opioid narcotics. Adolor’s strategy is to combine near-term commercialization opportunities with a longer-term approach to develop novel opioid analgesics based upon a new molecular understanding of the function of opioid receptors. Adolor combines the expertise of world leaders in molecular biology, pharmacology and chemistry with experienced pharmaceutical and biotechnology management. As Adolor moves towards commercialization, the company continues to add key personnel with clinical development, regulatory and commercialization expertise. The Company’s strategic goal is to establish a pharmaceutical franchise in pain management.
Aerogen, Inc. Mountain View, California
Aerogen, an emerging specialty pharmaceutical company, is developing inhaler and nebulizer products, based on its proprietary aerosol generator technology, for the treatment of respiratory disorders in the home and hospital markets. Aerogen is also applying its technology to develop products in collaboration with pharmaceutical and biotechnology companies for the treatment of respiratory and other disorders. Aerogen now markets two Aeroneb nebulizer systems, one optimized for professional use in the hospital and the other for home use.
Aeterna Laboratories, Inc. 1405 Parc-Technologique Blvd. Quebec City, Quebec, CANADA G1P 4P5
AEterna Laboratories has an extensive portfolio of marketed and development-stage biopharmaceutical products focused in oncology and endocrinology. Its lead oncology compound is Neovastat®, a proprietary angiogenesis inhibitor with multiple mechanisms of action in a Phase III clinical trial for renal cell carcinoma (data available by year-end 2003) and in a Phase III trial for non-small cell lung cancer. Cetrotide®, its lead compound in endocrinology is sold in the U.S. and Europe to the "in vitro" fertilization market, and is in clinical testing for endometriosis, uterus myoma and enlarged prostate (BPH). A further seven clinical programs are underway with various compounds. Email: paul.burroughs@aeterna.com
Alcon Laboratories, Inc. Fort Worth, Texas
From its inception more than 50 years ago, Alcon has committed itself to the discovery and development of specialty pharmaceuticals that address both chronic and acute diseases of the eye. We are committed not just to the treatment of a single eye disease or disorder, such as gluacoma, but to all of the major diseases of the eye including infection, inflammation, allergy, dry eye and macular degeneration. Over the years, Alcon has become the global leader in specialty ophthalmic pharmaceuticals, with the broadest array of products of any company in the industry around the world. With a large sales force covering ophthalmologists, optometrists, pediatricians, allergists and primary care physicians, we are uniquely positioned in the industry to market effectively to all physicians and eye care professionals who might prescribe our eye medications.
Alexion Pharmaceuticals Cheshire, Connecticut
Alexion's strategy is to build on its strong scientific and product development base to develop novel antibody therapeutics targeting the treatment of patients with a wide array of severe disease states, including cardiovascular and autoimmune disorders, inflammation and cancer. Alexion is dedicated to developing effective and safe treatments for human diseases for which treatment options are either non-existent or inadequate.
Alfacell Corporation 225 Belleville Avenue Bloomfield, New Jersey 07003
Alfacell is a biopharmaceutical company focused on the discovery, development and commercialization of novel ribonucleases (RNases). Our mission is to develop new therapeutics from our novel ribonuclease technology platform for the treatment of cancer, infectious diseases and other life threatening conditions, thus offering new horizons of hope for patients and physicians.
Email: info@alfacell.com
Allergan, Inc. Irvine, California
Allergan, Inc., with headquarters in Irvine, California, is a global specialty pharmaceutical company that develops and commercializes innovative products for the eye care, neuromodulator, skin care and other specialty markets. In addition to its discovery-to-development research programs, Allergan has global marketing and sales capabilities in over 100 countries that deliver value to our customers, satisfy unmet medical needs and improve people's lives.
Allos Therapeutics, Inc. 11080 CirclePoint Road Suite 200 Westminster, Colorado 80020
Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative drugs for improving cancer treatments. The company's lead clinical candidate, RSR13 (efaproxiral), is a synthetic small molecule that has the potential to sensitize hypoxic (oxygen deprived) tumor tissues and enhance the efficacy of standard radiation therapy. In addition, Allos is developing PDX, a novel small molecule cytotoxic injectable antifolate (DHFR inhibitor) being developed for non-small cell lung cancer, mesothelioma and non-Hodgkin's lymphoma. Email: mgreer@allos.com
Alnylam Pharmaceuticals, Inc. 790 Memorial Drive, Suite 202 Cambridge, Massachusetts 02139
Alnylam is the leading company in the emerging field of RNA interference (RNAi) whose vision is to Harness a Revolution in Biology for Human Health(TM). Growing from its foundation as the world's first company focused on RNAi-based therapeutics, the company is built around the leading capabilities of its two operating units, Alnylam Pharmaceuticals of Cambridge, Massachusetts, and Ribopharma of Kulmbach, Germany. Over the last several years, RNAi has been identified as a fundamental cellular mechanism for gene silencing. The company's leadership in the field of RNAi is supported by its preeminent founders and advisors and its strengths in fundamental patents, technology, and know-how that underlie the commercialization of RNAi-based therapeutics. The company's focus is to discover, develop, and commercialize therapeutic products based on RNAi for a broad range of therapeutic indications including viral, oncologic, metabolic, CNS and autoimmune diseases. The company's mission is to lead research in the field of RNAi, to build the leading pipeline of RNAi-based therapeutics, and to emerge as business leaders Email: rbean@alnylam.com
Alpha Therapeutic Corporation Los Angeles, California
Headquartered in Southern California, Alpha Therapeutic has offices and facilities throughout the United States. A subsidiary, Alpha Therapeutic Services, is a nationwide provider of home infusion products and services. In addition, the company has international affiliates in the United Kingdom, Germany, Spain, Italy, Thailand and Singapore.
Alpharma U.S. Pharmaceuticals Division Baltimore, Maryland
Marketing the broadest portfolio of specialty pharmaceuticals in the industry with over 150 products in both prescription and over-the-counter categories, Alpharma USPD is a major generic drug company with a substantial presence in consumer pharmaceuticals. Items are available in a wide range of product categories from respiratory and cough/cold to first aid and women's health. We are dedicated to providing our customers with the highest quality generic pharmaceuticals.
ALZA Corporation Mountain View, California
ALZA Corporation, headquartered in Mountain View, California, is a research-based pharmaceutical company with leading drug delivery technologies.
ALZA applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for many of the world's leading pharmaceutical companies as well as for its own portfolio. ALZA's strategy for building its commercial presence is to target specialty market opportunities, with a focus on urology, oncology and central nervous system (CNS) products. By developing, acquiring and marketing products in these areas, ALZA is establishing strong relationships with key physicians while providing a range of therapies to treat the individual needs of patients.
Amgen, Inc. Thousand Oaks, California
Amgen, the world's largest independent biotechnology company, was founded in Thousand Oaks, California in 1980 as AMGen (Applied Molecular Genetics). At the time, Amgen's corporate mission was to be the world leader in discovering, developing and manufacturing cost-effective human therapeutics based on advances in cellular and molecular biology.
Currently, Amgen's Aspiration statement is to be the best human therapeutics company. We will live the Amgen values and use science and innovation to dramatically improve people's lives.
In-depth knowledge developed through the utilization of state-of-the-art cellular and molecular biology enables Amgen scientists to discover and develop both naturally occurring proteins and small molecules as potential human therapeutics.
Amylin Pharmaceuticals, Inc. 9373 Towne Centre Drive San Diego, California 92121
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing innovative medicines to improve the lives of people with metabolic diseases. The Company’s two late-stage, first-in-class diabetes product candidates – SYMLIN® (pramlintide acetate) and exenatide (synthetic exendin-4) – are being developed to address the global epidemic of diabetes. Amylin has a strategic alliance with Eli Lilly and Company for the co-development and global commercialization of exenatide, and an extended release formulation, exenatide LAR. Building on its experience in the diabetes field, the Company is developing candidates for cardiovascular disease and obesity by utilizing its research experience with the metabolic properties common to all three conditions. Email: IR@amylin.com
Andrx Corporation Weston, Florida
Andrx Corporation is a specialty pharmaceutical company that applies its ten proprietary and patented oral controlled-release drug delivery technologies and formulation skills to the research and develoment of bioequivalent/generic (ANDA) and brand/proprietary (NDA) products. In its generic program, Andrx primarily develops bioequivalent versions of controlled-release brand products as well as difficult to replicate specialty, niche or immediate release brand name pharmaceuticals. In its brand program, Andrx applies its oral controlled-release technologies and formulation skills to develop improved versions of existing brand drugs, which will be marketed as new brand pharmaceuticals. Andrx also markets and distributes, primarily to independent pharmacies, pharmaceutical products manufactured by third parties.
Angiogene Pharmaceuticals Ltd. Oxfordshire, United Kingdom
Angiogene is a drug discovery company targeting diseases involving active angiogenesis. The company was originally formed in 1993 to exploit the expertise and intellectual property of the founding scientist, Dr. Graeme J. Dougherty, in the areas of gene therapy and vascular biology. Angiogene established its U.K. Office in 1996 and was registered in Scotland in 1997 as Angiogene Pharmaceuticals Ltd. The company's research is presently carried out at laboratories in the U.K. and in North America. In 1998 Angiogene secured its first major partnership with a large pharmaceutical company, licensing ANG453 to AstraZeneca. Renamed ZD6126, this compound is now in Phase I. Email: pdd@angiogene.co.uk
Arbor Pharmaceuticals, Inc. 4505 Falls of the Neuse Road, Suite 420 Raleigh, North Carolina 27609
Arbor Pharmaceuticals is a Raleigh, North Carolina based specialty
pharmaceutical company focused on the licensing, development, and
commercialization of products for pediatricians. Founded in 2006, Arbor
actively seeks out unique, patent-protected therapies proven to effectively
treat common pediatric illnesses. Arbor Pharmaceuticals collaborates with
pharmaceutical development companies and established promotional partners in
the pharmaceutical industry to develop and market their products in order to
serve the needs of pediatricians throughout the US. Email: info@arborpharma.com
Astellas Pharma Inc. 3-11, Nihonbashi-Honcho 2-Chome, Chuo-Ku Tokyo, Japan
Manufacturing, marketing and import/export of pharmaceuticals, quasi-drugs, foods and medical supplies and systems, and home care business, etc.
Astellas Pharma was formed from the merger of Fujisawa Pharmaceuticals and Yamanouchi Pharmaceuticals in April 2005.
AstraZeneca Corporation London, United Kingdom
AstraZeneca is one of the world's leading pharmaceutical companies. Backed by a strong research base and extensive manufacturing and commercial skills, we provide innovative, effective medicines that make a real difference for patients in important areas of healthcare. We aim to be the first with new ideas and innovative in all areas of our activity to create value for our customers, shareholders, employees and the communities in which we work.
AstraZeneca provides innovative, effective medicines designed to fight disease in important areas of medical need: cancer, cardiovascular, central nervous system, gastrointestinal, infection, pain control and respiratory.
AtheroGenics, Inc. 8995 Westside Parkway Alpharetta, Georgia 30004
AtheroGenics is an emerging pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, rheumatoid arthritis and asthma.
AtheroGenics has cultivated a drug discovery and development capability directed toward rapidly creating and transporting small molecule therapeutics into the clinical testing arena to ultimately establish the safety and efficacy of novel compounds that address serious unmet medical needs
AtheroGenics has assembled two synergistic technology platforms. Our proprietary v-protectantTM technology platform has been the foundation of our discovery research efforts, and is the basis of our first three compounds, currently in clinical development. Email: investor@atherogenics.com
AVANIR Pharmaceuticals San Diego, California
AVANIR Pharmaceuticals is a drug discovery and development company that has a commercialized FDA-approved product and a product in Phase III clinical trials. AVANIR is engaged in small molecule research to develop treatments for central nervous system disorders and inflammatory diseases. Through its subsidiary, Xenerex Biosciences, AVANIR also develops human monoclonal antibodies for therapeutic applications.
Aventis US Bridgewater, New Jersey
Aventis is now part of the sanofi-aventis Group.
The sanofi-aventis Group is the world’s 3rd largest pharmaceutical company, ranking number 1 in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine, and vaccines.
. Email: info@aventis-us.com
AVI BioPharma (AVI) One SW Columbia Suite 1105 Portland, Oregon 97258
AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using two technology platforms: third-generation NEUGENE antisense drugs and cancer immunotherapy. AVI's lead NEUGENE antisense compound is designed to target cardiovascular restenosis, cancer, polycystic kidney disease and other cell proliferation disorders. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to target single-stranded RNA viruses, including West Nile virus, SARS coronavirus, calicivirus and hepatitis C. AVI's second technology, AVICINE®, is a therapeutic cancer vaccine with late-stage trials planned for the treatment of pancreatic and colorectal cancer. Email: avi@avibio.com
Axcan Pharma, Inc. Mont-Saint-Hilaire, Québec, Canada
Axcan is a leading specialty pharmaceutical company within the field of gastroenterology in North America and Europe. Axcan markets a broad line of pharmaceutical products used in the treatment of a variety of gastrointestinal diseases and disorders. In addition to its marketing activities, Axcan carries out research and development of products at an advanced stage of development that it acquires or licenses from third parties. By combining its marketing expertise with its research and development experience, Axcan distinguishes itself from specialty pharmaceutical companies that focus solely on distribution of products and offers potential licensors the prospect of rapidly expanding the potential market for their products.
Axonyx Inc. New York, New York
Axonyx Inc. is a U.S.-based biopharmaceutical company engaged in the acquisition and development of proprietary pharmaceutical compounds and new technologies useful in the diagnosis and treatment of Alzheimer's Disease, human memory disorders and prion-based illnesses such as Mad Cow Disease.
Public
Feeds 
